切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2010, Vol. 04 ›› Issue (03) : 313 -321. doi: 10.3877/cma.j.issn.1674-0807.2010.03.012

临床研究

纳米炭对乳腺癌腋窝淋巴结示踪效果及其安全性的初步研究
范林军1, 钟玲1, 郭德玉2, 贺青卿1, 姜军1   
  1. 1.400038 重庆,第三军医大学西南医院乳腺疾病中心
    2.400038 重庆,第三军医大学西南医院病理科
  • 收稿日期:2010-06-24 出版日期:2010-06-01

Effect and safety of carbon nanoparticles dyeing in axillary lymph node dissection of breast cancer

Lin-jun FAN1, Ling ZHONG1, De-yu GUO1, Qing-qing HE1, Jun JIANG1   

  1. 1.Breast Disease Center,Southwest Hospital,Third Military Medical University,Chongqing 400038,China
  • Received:2010-06-24 Published:2010-06-01
引用本文:

范林军, 钟玲, 郭德玉, 贺青卿, 姜军. 纳米炭对乳腺癌腋窝淋巴结示踪效果及其安全性的初步研究[J/OL]. 中华乳腺病杂志(电子版), 2010, 04(03): 313-321.

Lin-jun FAN, Ling ZHONG, De-yu GUO, Qing-qing HE, Jun JIANG. Effect and safety of carbon nanoparticles dyeing in axillary lymph node dissection of breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2010, 04(03): 313-321.

目的

探讨国产纳米炭混悬液对腋窝淋巴结的示踪效果及其安全性。

方法

2008年5月至2009年9月间对21例乳腺癌患者在术前采用纳米炭进行淋巴结示踪。患者年龄30~65岁,平均45.3岁。术前24~72 h于乳晕周围分4点皮下均匀注射纳米炭混悬液共1 ml。手术方式采用改良根治术5例,腔镜下乳房皮下腺体切除、腋窝淋巴结清除加假体植入术12例,乳腺癌局部扩大切除加腔镜腋窝淋巴结清除术4例。术后观察腋窝淋巴结的黑染情况并送病理检查。

结果

21例患者分别检出淋巴结14~32枚,平均每例21.5枚,共452枚。肉眼下黑染淋巴结共435枚,黑染率为96.3%(435/452),其中明显黑染率为85.4%(386/452)。腋窝淋巴结无转移6例,有转移15例。有转移的淋巴结共45枚,均为明显黑染淋巴结,转移淋巴结黑染率为100%。经病理证实,未黑染的淋巴结均未出现癌转移。所有患者经8个月至2年的随访,均未出现复发转移及明显肝肾功能异常。有纳米炭残留的局部组织在术后1年行活组织检查,见乳腺组织间隙有较多的纳米炭颗粒沉集,但未见明显的炎症反应或组织变性。

结论

纳米炭混悬液经乳晕周围皮下注射后24~72 h行腋窝淋巴结清除可达到良好的淋巴结示踪效果,有效避免转移淋巴结的漏检。残留体内的纳米炭无明显的毒副反应。纳米炭是一种安全可靠的腋窝淋巴结示踪剂。

Objective

To explore the dyeing effect and safety of cabon nanoparticles suspension in axillary lymph node dissection of breast cancer.

Methods

From May 2008 to September 2009,21 patients with breast cancer aged 30-65 years(mean,45.3 years)underwent lymphatic tracing with carbon nanoparticles preoperatively. The carbon nanoparticles suspension(1 ml)was subcutaneously injected around the areola at 24-72 hours before operation.Then radical mastectomy in 5 cases,endoscopic subcutaneous mastectomy plus axillary lymph node dissection and immediate reconstruction with implants in 12 cases and breast conserving surgery in 4 cases were performed.After operation,the lymph nodes were dissected and pathologically examined to observe the dyeing status.

Results

The number of blackened lymph nodes ranged from 14 to 32,with a mean of 21.5 per case.The blacking rate under naked eye was 96.3%(435/452),among which obviously blacking rate was 85.4%(386/452).A total of 45 metastatic axillary lymph nodes that were stained obviously black were found in 15 patients,thus the blacking rate of metastatic lymph nodes was 100%.The rest 6 patients showed no metastatic axillary lymph nodes.No black-staining of axillary lymph nodes indicated no metastasis.All patients were followed up for 8 months to 2 years,and no tumor recurrence,metastasis or dysfunction of liver and kidney was found.Carbon nanoparticles deposition was observed microscopically in breast stroma around the injection sites within 1 year after operation,but no inflammatory reaction or tissue degeneration occurred.

Conclusion

A satisfactory effect of lymphatic tracing could be obtained in axillary lymph node dissection at 24-72 hours after the carbon nanoparticles suspension was subcutaneously injected around the areola,and the omission of metastatic lymph nodes could be validly avoided.There was no obviously toxic effect and adverse reaction of residue carbon nanoparticles in vivo.Therefore,carbon nanoparticles suspension is a safe and reliable axillary lymphatic tracer.

图1 纳米炭混悬液乳晕周围皮下注射示意图
图2 淋巴结不同染色程度示意图 a、b为明显黑染;c-e为轻度黑染;f、g为无明显黑染
图3 术中黑染淋巴结示意图 淋巴结黑染后清晰易辨(箭头指示),甚至腋静脉上方的淋巴结也被明显黑染(左上箭头指示)。
图4 某例乳腺癌患者腋窝淋巴结示意图 术前3 d乳晕周围皮下注射纳米炭,腋窝清除术后分离出的淋巴结17枚全被染成黑色。
图5 纳米炭黑染淋巴结的显微镜下形态(HE染色 ×40) 大量纳米炭颗粒滞留在边缘窦和中央窦中。
图6 癌转移淋巴结的显微镜下形态(HE染色 ×200) 纳米炭颗粒被巨噬细胞吞噬。
图7 纳米炭混悬液注射后局部皮肤改变 乳晕周围皮下注射后24h,纳米炭在皮下有一定程度的扩散,但未出现局部红肿或炎症反应。
图8 残留纳米炭组织的显微镜下形态(HE染色 ×200) 纳米炭示踪并行局部扩大切除术后1年,病理活组织检查显示乳腺间质中仍有较多纳米炭颗柆残留,但炭颗粒周围未见明显间质反应。
[1]
Chua B,Ung O,Taylor R,et al.Frequency and predictors of axillary lymph node metastases in invasive breast cancer.ANZ J Surg,2001,71:723-728.
[2]
Cunnick GH,Jiang WG,Gomez KF,et al.Lymphangiogenesis and breast cancer metastasis.Histol Histopathol,2002,17:863-870.
[3]
Early Breast Cancer Trialists'Collaborative Group(EBCTCG).Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet,2005,366,2087-2106.
[4]
Kim T,Giuliano AE,Lyman GH.Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma:a meta analysis.Cancer,2006,106:4-16.
[5]
Lyman GH,Giuliano AE,Somerfield MR,et al.American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol,2005,23:7703-7720.
[6]
Veronesi U,Paganelli G,Viale G,et al.Sentinel lymph node biopsy as a staging procedure in breast cancer:update of a randomized controlled study.Lancet Oncol,2007,7:983-989.
[7]
范林军,姜军.全腔镜乳腺癌改良根治手术技术.中华乳腺病杂志:电子版,2010,4:11-14.
[8]
Fiorito S,Serafino A,Andreola F,et al.Toxicity and biocompatibility of carbon nanoparticles.J Nanosci Nanotechnol,2006,6:591-599.
[9]
Yokota T,Saito T,Narushima Y,et al.Lymph-node staining with activated carbon CH40:a new method for axillary lymphnode dissection in breast cancer.Can J Surg,2000,43:191-196.
[10]
郑春雷,许军.国产纳米活性炭在胃癌根治术中的应用.齐齐哈尔医学院学报,2008,29:275-277.
[11]
雷建,黄炯强,胡明,等.活性炭示踪指导进展期胃癌手术淋巴结清除的意义.岭南现代临床外科,2008,8:187-188.
[12]
于永扬,王存,郑阳春,等.比较研究纳米炭示踪剂在低位直肠癌淋巴结清除及病理检查中的价值.中国普外基础与临床杂志,2008,15:358-361.
[13]
秦平,张海燕,龙泉伊,等.纳米炭示踪剂在乳腺癌淋巴结转移的价值和运用.华西医学,2009,24:864-865.
[14]
Tongeren MJ,Kromhout H,Gardiner K.Trends in levels of inhalable dust exposure,exceedance and overexposure in the European carbon black manufacturing industry.Ann Occup Hyg,2000,44:271-280.
[15]
Magrez A,Kasas S,Salicio V,et al.Cellular toxicity of carbon-based nanomaterials.Nano Lett,2006,6:1121-1125.
[16]
Ito T,Hagiwara A,Takagi T,et al.Local administration of methotrexate bound to activated carbon particles for treating cancers in mice.Anticancer Res,2003,23:1401-1404.
[17]
Kuru B,Bozgul M.The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma.Int J Radiat Oncol Biol Phys,2006,66:1328-1334.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要